Beijing, China (PRWEB) May 11, 2013

Puhua International Hospitals (PIHs)-Temple of Heaven (http://www.puhuahospital.com), (http://www.puhuachina.com) has been a leading international neuroscience and biotechnology center in Beijing, China, for the past 20 years. During that time, Puhua International has achieved a dominant presence in Beijing, China, in applied biotechnology, cellular biotherapy, neurology, neurosurgery, medicine, cancer, traditional Chinese medicine (TCM) and surgery.

Puhua International is the only international hospital in Beijing to routinely evaluate, treat and admit a wide range of international patients. In fact, Puhua International was one of the first of what are now known as medical tourism facilities in Asia, and the level of expertise and care for all international patients is currently unrivaled. Patients repeatedly report in quality-control surveys that the International Service Department at Puhua International is unrivaled for quality and outstanding level of no-problems service. Patients come to this hospital with diagnoses ranging from metabolic, genetic and genetic disorders to central nervous system (brain and spinal cord) injury and trauma; glioma; seizure disorders; cerebral palsy; Parkinson's disease and a wide range of neuropathic and myopathic disorders. PIH also has vigorous programs of integrative oncology and diabetes.

Over the past decade Puhua International Hospitals-Temple of Heaven has made huge strides forward in applied cellular biotechnology (stem cell therapy, or SCT). Thus, in addition to its high level of diagnostic and therapeutic expertise, PIH has become a world leader in applied biotechnology, cellular science and applied stem cell technology. It is in these areas of applied clinical biotechnology that remarkable progress is being made at PIH in the areas of: spinal cord repair; post-traumatic brain injury; cerebral palsy; Parkinsons disease; cerebral-vascular and cardio-vascular disease, and diabetes. Other conditions managed at PIH include the management of difficult tumors and cancers, metabolic diseases and genetic disorders. By utilizing cellular/regenerative medicine and biotechnology at the time of surgical repair for spinal cord and brain injury, the neurosurgeons and clinical scientists at PIH are today redefining what is possible in recovery from neurological injury and disease.

Whereas traditional SCT utilizes donor cell-lines (for example, mesenchymal stem cells derived from donor placental cord blood), newer pathways using autologous stem cells (meaning stem cell lines derived from the patients own cells) are now also being successfully employed. Autologous stem cellular therapy is extremely safe and cost-effective for younger (under 40 years of age) patients with diagnoses such as: cerebral palsy, anoxic encephalopathy, autism, diabetes and many other problems.

Puhua International Hospitals-Temple of Heaven, Beijing (http://www.puhuahospital.com) (http://www.puhuachina.com) is thus a Center of Excellence in neurology and neurosurgery as well as a leader on the new frontier of applied stem cell science and biotechnology.

James T. Quinlan, MD, is an American physician, trained at the University of Iowa, with a life-long interest and commitment to the subject of wellness, regenerative medicine and anti-aging. He is heading the international initiative at Puhua International Hospitals (PIH)-Temple of Heaven. The goal is to apply what has been learned in the past decade of applied stem cell science to the important and fascinating frontiers of anti-aging/regenerative medicine, diabetes, heart failure and cancer as well as the range of neurologic, metabolic and genetic diseases.

It is toward the goal of expanding its world-wide referral base that Puhua International Hospitals (PIHs)-Temple of Heaven announces its request that serious and suitable candidates who are interested in serving as international referring agents to PIHs submit their Bio and/or CV to info(at)puhuachina(dot)com for evaluation and consideration. A pre-requisite to become a Puhua International Partner is a Bachelors Degree (or higher) and experience in a health-related field. Special consideration will be given to those candidates who possess medical backgrounds and/or experience. Valued attributes include a high level of inter-personal skills, facility with marketing concepts/experience and polished communication skills.

The Puhua International Partnership seeks greater presence in Africa, the Americas, Asia, Europe, India, South East Asia and the U.K. All training and orientation for these positions will be undertaken and underwritten by Puhua International Hospitals (PIH)-Temple of Heaven. Individuals who are already positioned to understand stem cell science, and who are also in a position to reach out through their local and regional media to patients most likely to benefit from advanced cellular therapy are encouraged to contact us at info(at)puhuachina(dot)com.

After many treating many thousands of patients with mesenchymal stem cells, we know that this technique is safe and generally effective, and the stem cells themselves are the stars in this process. Their extremely low antigenicity coupled with their predilection to go to where they are needed, blend in with the hosts own (and older) stem cells and then go on to differentiate in harmony with these older cells makes the technical aspects of this process very straight-forward. Still, not every question has been answered. Thus, while offering an anti aging and many other stem cell therapies, Puhua International is also coupling these treatments to prospective clinical studies in the search to expand medical knowledge.

Continued here:
Puhua International Hospitals (PIHs): Soliciting Agents for World-wide Referral Network

A team of 70 scientists from the United States, China, Australia and Japan reports having sequenced and annotated the genome of the "sacred lotus," which is believed to have a powerful genetic system that repairs genetic defects, and may hold secrets about aging successfully.

The scientists sequenced more than 86 percent of the nearly 27,000 genes of the plant, Nelumbo nucifera, which is revered in China and elsewhere as a symbol of spiritual purity and longevity.

"The lotus genome is an ancient one, and we now know its ABCs," said Jane Shen-Miller, one of three corresponding authors of the research and a senior scientist with UCLA's Center for the Study of Evolution and the Origin of Life. "Molecular biologists can now more easily study how its genes are turned on and off during times of stress and why this plant's seeds can live for 1,300 years. This is a step toward learning what anti-aging secrets the sacred lotus plant may offer."

The research was published today in the journal Genome Biology.

Shen-Miller said the lotus' genetic repair mechanisms could be very useful if they could be transferred to humans or to crops such as rice, corn and wheat whose seeds have life spans of only a few years. "If our genes could repair disease as well as the lotus' genes, we would have healthier aging. We need to learn about its repair mechanisms, and about its biochemical, physiological and molecular properties, but the lotus genome is now open to everybody."

In the early 1990s, Shen-Miller led a UCLA research team that recovered a viable lotus seed that was almost 1,300 years old from a lake bed in northeastern China. It was a remarkable discovery, given that many other plant seeds are known to remain viable for just 20 years or less.

In 1996, Shen-Miller led another visit to China. Working in Liaoning province, her team collected about 100 lotus seeds - most were approximately 450 to 500 years old - with help from local farmers. To the researchers' surprise, more than 80 percent of the lotus seeds that were tested for viability germinated. That indicated that the plant must have a powerful genetic system capable of repairing germination defects arising from hundreds of years of aging, Shen-Miller said.

Understanding how the lotus repair mechanism works and its possible implications for human health is essentially a three-step process, said Crysten Blaby-Haas, a UCLA postdoctoral scholar in chemistry and biochemistry and co-author of the research. "Knowing the genome sequence was step one. Step two would be identifying which of these genes contributes to longevity and repairing genetic damage. Step three would be potential applications for human health, if we find and characterize those genes. The genome sequence will aid in future analysis.

"The next question is what are these genes doing, and the biggest question is how they contribute to the longevity of the lotus plant and its other interesting attributes," Blaby-Haas said. "Before this, when scientists studied the lotus, it's almost as if they were blind; now they can see. Once you know the repertoire of genes, you have a foundation to study their functions."

The genome sequence reveals that, when compared with known gene sequences of dozens of other plants, the lotus bears the closest resemblance to the ancestor of all eudicots, a broad category of flowering plants that includes the apple, peanut, tomato, cotton, cactus and tobacco plants.

Read the original post:
Genome of lotus may hold anti-aging secrets

Houston, TX (PRWEB) May 07, 2013

PreDiabetes Centers, the nationwide leader in customized prediabetes treatment, today announced the opening of a new location in Houston and the appointment of Dr. Meg Qayum to lead the treatment center. Dr. Qayum is a board-certified physician with many years of experience in treating chronic disease. As a prediabetes physician, she will direct medical care for patients enrolled in the Companys 12-month comprehensive treatment program.

Dr. Qayum specializes in integrative and functional medicine. She received her medical degree and residency training from Louisiana State University School of Medicine in New Orleans. She is a member of the Fellowship in Anti-Aging and Regenerative Medicine, the Institute for Functional Medicine, and the American College for Advancement in Medicine. Dr. Qayum served as the Wellness Director of Divinity Med Spa & Wellness where she used a combination of bioidentical hormone therapy and customized nutrition and fitness therapy to treat people with hormone imbalance conditions, including weight gain, loss of energy, low libido, stress and depression.

She will meet with clients at the PreDiabetes Center of North Houston at 13688 Breton Ridge Street, Suite F.

Dr. Qayum is excited about incorporating a multi-faceted approach to prediabetes care. This is the first program that looks at all contributing factors of the disease, she said, noting that the program uses continuous biomarker tests to ensure that individual markers of health are improving in conjunction with treatment.

Dr. Qayum says that people with prediabetes need targeted medical treatment in order to prevent the development of type 2 diabetes.

You cant treat a chronic disease on your own. [Prediabetics] need a team approach to help guide them through [treatment], said Dr. Qayum.

She notes that even if a person never progress to diabetes, he or she still has harmful conditions occurring in the body, such as inflammation, high blood pressure or abnormal cholesterol levels, that can lead to long-term health problems. A comprehensive prediabetes treatment plan targets these underlying imbalances and can help reverse their devastating effects.

Dr. Qayum said that many factors contribute to a prediabetes diagnosis, but nutrition, in particular, is a serious problem.

People who are in their 30s and 40s were raised in a generation when soft drinks werent considered bad, says Dr. Qayum.

See more here:
Dr. Meg Qayum Leads Prediabetes Treatment Center in Houston

What can I do with my unwanted body fat? That is a question that is posed by American CryoStem (OTCQB:CRYO - News) on the home page of its website. There are plenty of finite resources in the world, but lets face it, body fat certainly isnt one of them. A little due diligence reveals the companys answer to that question, but a more discerning examination uncovers the true growth potential of American CryoStem from an immediate, mid-term and long-term perspective.

American CyroStem is pioneering uses for adipose (fat) tissue-based cellular technologies in the field of regenerative and personalized medicine, two industries that are likely to assume dominant roles in the future of health care. It should be recognized that the company is still a small firm with limited resources, but our discussions with chief executive and chairman John Arnone unveil a succinct business model and allocation of those resources to shepherd the company to a far greater vision and valuation.

Short Term Revenue

In the present, the company has started generating revenue through its network of physicians with ATGRAFT, a service for processing and storing adipose tissue for layered fat transfers and reconstructive procedures. Another attractive example of this type of present revenue is with Personal Cell Sciences (PCS), the maker of the upscale UAutologous line of stem cell-based skin care products, which delivers high margins for American CryoStem. The sales channel works through cosmetic surgeons, clinics and other organizations in the extensive PCS/CRYO network offering physicians different options to offer patients to use their adipose derived cells, cells that are loaded with human growth factors, cytokines and matrix proteins. American CryoStem receives the adipose tissue for processing and storage, adding one-time cash to its coffers for the processing services as well as recurring revenue for storage of the stem cells.

International Stem Cell Corporation (OTCBB:ISCO - News) offers a somewhat comparable product, Lifeline Skin Care. The Lifeline product relies on stem cells derived from unfertilized human eggs, and the company touts that their process insures minimal immune rejections and can be used by people of all genders, ages and racial backgrounds. American Cryostems approach goes one step further by using the patients very own stem cells as the basis for its products.

In April, the company penetrated the Asian markets through receipt of its first commercial shipment of adipose tissue for processing, long-term cryo-storage and formulation of the U-Autologous anti aging product, from Biomedical and Life Sciences Institute, a Hong Kong-based regenerative medicine company and distribution relationship of PCS.

While the U.S. markets are formidable as part of the $30.5 billion cosmeceutical industry, the Asian markets represent a substantial opportunity. A cultural shift is happening in major markets around the world. After centuries of repressing individualization, people are showing off their wealth with imported products, such as high-end cosmetics from the United States and Europe, being chic and symbolic of status.

Medium Term Growth

Additionally, American CryoStem is building out its cell culture medium offerings that have the potential to revolutionize the business. The current global medium of choice for culturing stem cells utilizes fetal bovine serum (FBS), and thats exactly as the name implies. FBS comes from bovine fetuses and, while generally accepted, there are ethical and biological arguments against the standard today. There has been talk for years of a dynamic shift to remove any trace of an animal component in the supply chain in specified risk materials in the European Union, not to mention the fact that human albumen based serums may be statistically superior to the fetal bovine serums.

American CryoStem has been awarded a series of patents with more pending on its proprietary formulation for non-animal based serums. With or without global initiatives mandating change, this aspect of the company offers a substantial upside in coming years as the biotechnology industry becomes more aware of benefits of the new medium. Simply, the company is at the forefront of the multi-billion-dollar business.

Read more from the original source:
The Beauty of American CryoStem Now and in the Future